Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$39.53
+1.2%
$32.54
$23.42
$62.58
$2.26B0.73656,495 shs978,020 shs
Alkermes plc stock logo
ALKS
Alkermes
$30.46
+1.6%
$30.18
$22.97
$36.45
$4.94B0.441.74 million shs1.38 million shs
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
$51.99
$51.95
$14.95
$52.00
$3.71B1.221.68 million shs113 shs
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
$47.99
$47.99
$19.64
$48.02
$2.27B1.051.16 million shs30,200 shs
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
$42.97
$42.83
$32.67
$45.76
$1.62B0.5645,199 shsN/A
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
+1.18%+9.64%+14.55%+48.05%-9.11%
Alkermes plc stock logo
ALKS
Alkermes
+1.60%+5.95%-1.93%+12.81%+32.38%
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
0.00%0.00%0.00%0.00%0.00%
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
4.119 of 5 stars
3.41.00.04.31.90.81.9
Alkermes plc stock logo
ALKS
Alkermes
4.9174 of 5 stars
4.43.00.04.22.92.51.9
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
N/AN/AN/AN/AN/AN/AN/AN/A
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
2.71
Moderate Buy$58.6048.24% Upside
Alkermes plc stock logo
ALKS
Alkermes
2.83
Moderate Buy$40.0031.32% Upside
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
0.00
N/AN/AN/A
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
0.00
N/AN/AN/A
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest RARX, ALKS, TARO, AGIO, and CCXI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Alkermes plc stock logo
ALKS
Alkermes
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$33.00 ➝ $42.00
5/28/2025
Alkermes plc stock logo
ALKS
Alkermes
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral ➝ Buy$45.00
5/13/2025
Alkermes plc stock logo
ALKS
Alkermes
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/2/2025
Alkermes plc stock logo
ALKS
Alkermes
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
5/2/2025
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$74.00 ➝ $71.00
5/2/2025
Alkermes plc stock logo
ALKS
Alkermes
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$39.00 ➝ $40.00
5/2/2025
Alkermes plc stock logo
ALKS
Alkermes
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$38.00 ➝ $41.00
4/28/2025
Alkermes plc stock logo
ALKS
Alkermes
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingUnderperform ➝ Underperform
4/28/2025
Alkermes plc stock logo
ALKS
Alkermes
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform
4/28/2025
Alkermes plc stock logo
ALKS
Alkermes
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$38.00 ➝ $33.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$36.50M62.73N/AN/A$27.02 per share1.46
Alkermes plc stock logo
ALKS
Alkermes
$1.51B3.32$2.69 per share11.31$9.05 per share3.37
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
$32.22M115.14N/AN/A$4.09 per share12.71
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
$3M757.11N/AN/A$5.56 per share8.63
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
$629.18M2.57$2.38 per share18.03$47.70 per share0.90
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$673.72M$11.243.52N/AN/A1,798.26%-2.75%-2.52%7/30/2025 (Estimated)
Alkermes plc stock logo
ALKS
Alkermes
$367.07M$2.0914.5722.231.8623.30%27.52%17.98%7/23/2025 (Estimated)
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
-$131.76M-$1.89N/AN/AN/A-357.01%-48.52%-30.59%N/A
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
-$102.69M-$2.31N/AN/AN/AN/A-44.61%-41.60%N/A
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
$53.87M$1.4429.84N/A8.56%3.75%3.09%N/A

Latest RARX, ALKS, TARO, AGIO, and CCXI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-$1.74N/AN/AN/AN/AN/A
7/23/2025Q2 2025
Alkermes plc stock logo
ALKS
Alkermes
$0.42N/AN/AN/A$343.20 millionN/A
5/1/2025Q1 2025
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-$1.80-$1.55+$0.25-$1.55$9.86 million$8.73 million
5/1/2025Q1 2025
Alkermes plc stock logo
ALKS
Alkermes
$0.32$0.13-$0.19$0.13$307.53 million$306.51 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/AN/AN/AN/AN/A
Alkermes plc stock logo
ALKS
Alkermes
N/AN/AN/AN/AN/A
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
N/AN/AN/AN/AN/A
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
N/AN/AN/AN/AN/A
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/A
18.50
17.93
Alkermes plc stock logo
ALKS
Alkermes
N/A
3.33
2.92
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
0.02
4.54
4.47
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
0.01
14.78
14.79
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
N/A
3.61
3.04
CompanyEmployeesShares OutstandingFree FloatOptionable
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
39057.92 million55.43 millionOptionable
Alkermes plc stock logo
ALKS
Alkermes
1,800164.90 million157.65 millionOptionable
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
17871.36 million65.43 millionOptionable
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
7247.33 millionN/AOptionable
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
1,55437.59 million32.40 millionOptionable

Recent News About These Companies

FDA approves first generics of anticoagulant Xarelto
Taro to acquire 100% stake in Antibe Therapeutics
Sun Pharma unit poised to buy Canadian biotech Antibe

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Agios Pharmaceuticals stock logo

Agios Pharmaceuticals NASDAQ:AGIO

$39.53 +0.46 (+1.18%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$38.57 -0.96 (-2.43%)
As of 07/10/2025 05:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Alkermes stock logo

Alkermes NASDAQ:ALKS

$30.46 +0.48 (+1.60%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$29.94 -0.52 (-1.72%)
As of 07/10/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

ChemoCentryx stock logo

ChemoCentryx NASDAQ:CCXI

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.

Ra Pharmaceuticals stock logo

Ra Pharmaceuticals NASDAQ:RARX

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment. The company's pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases. It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement program targets, and provide research and development services. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Taro Pharmaceutical Industries stock logo

Taro Pharmaceutical Industries NYSE:TARO

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt. As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.